Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain
Status:
Completed
Trial end date:
2018-09-24
Target enrollment:
Participant gender:
Summary
The goal of this study is to compare the effectiveness of two different medications used in
intravaginal trigger point injections (injections into extremely painful areas of a muscle)
to treat chronic pelvic pain. The study compares onabotulinumtoxinA (BOTOX®) (a drug prepared
from the bacterial toxin botulin which temporarily paralyzes muscles) to Kenalog (a synthetic
corticosteroid used as an anti-inflammatory agent).
Phase:
N/A
Details
Lead Sponsor:
Jamie Bartley Jamie Bartley, DO
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA Triamcinolone Triamcinolone Acetonide Triamcinolone diacetate Triamcinolone hexacetonide